Our Team

Daniel R. Vlock, MD

Founder, Principal
Chief Executive Officer

Dr. Vlock brings extensive pharmaceutical industry and academic experience in pharmaceutical drug development. Dr. Vlock is founder and CEO of Alopexx Pharmaceuticals which is developing a fully human monoclonal antibody directed against S. aureus.  He has also held senior-level medical and research positions at GPC Biotech, Inc., Pharmacia Corporation, Ethicon Endo-Surgery (a subsidiary of Johnson… Read More »

Christine de los Reyes, Pharm. D.

Co-Founder, Principal
Strategic Planning and Business Development

Christine de los Reyes has over twenty five years of pharmaceutical experience and most recently was founder and Managing Director of BiotechPartnering Solutions, a business development consulting firm that advises life science companies on partnering strategy, search for potential partners, coordination of technical evaluation and due diligence, deal structure and transaction negotiation. In this capacity, she… Read More »

Deborah Ramsdell

Co-Founder, Principal
Development Operations and Regulatory Affairs

Deborah Ramsdell has 30 years of experience in the design and implementation of development strategies for therapeutic drugs and biotechnology products.   Over the course of her career, she has been responsible for the strategic design operational oversight of more than 70 drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious… Read More »

Hal Landy, MD

Chief Medical Officer

Dr. Landy is a board certified Pediatric Endocrinologist with over 30 years of clinical research experience in academics and industry, primarily in rare diseases. Educated at Harvard College (AB ’72) and Columbia University (MD ’81), he trained at Massachusetts General Hospital and at Children’s Hospital, Boston and was on staff at Children’s Hospital and Harvard… Read More »